Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2015', provides an overview of the Prader-Willi Syndrome (PWS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prader-Willi Syndrome (PWS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prader-Willi Syndrome (PWS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Prader-Willi Syndrome (PWS) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Prader-Willi Syndrome (PWS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Prader-Willi Syndrome (PWS) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Prader-Willi Syndrome (PWS)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Prader-Willi Syndrome (PWS) Overview 6
Therapeutics Development 7
Pipeline Products for Prader-Willi Syndrome (PWS) - Overview 7
Pipeline Products for Prader-Willi Syndrome (PWS) - Comparative Analysis 8
Prader-Willi Syndrome (PWS) - Therapeutics under Development by Companies 9
Prader-Willi Syndrome (PWS) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Prader-Willi Syndrome (PWS) - Products under Development by Companies 13
Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development 14
Chong Kun Dang Pharmaceutical Corp. 14
Essentialis, Inc. 15
Ferring International Center S.A. 16
LG Life Sciences, Ltd. 17
P2D Bioscience 18
Pfizer Inc. 19
Rhythm Pharmaceuticals 20
Prader-Willi Syndrome (PWS) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
beloranib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
betahistine hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
diazoxide choline CR - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
FE-992097 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
NOX-B11 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
setmelanotide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
somatropin SR - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Prader-Willi Syndrome (PWS) - Recent Pipeline Updates 42
Prader-Willi Syndrome (PWS) - Product Development Milestones 47
Featured News & Press Releases 47
Nov 14, 2014: Essentialis To Present Clinical Update At The Annual Research Conference Of The Foundation For Prader-Willi Research 47
Oct 01, 2014: Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome 47
Jul 23, 2014: Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome 48
Jul 10, 2014: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome 48
Jun 27, 2014: Essentialis Announces the Dosing of the First Patient in a Clinical Study of DCCR in Prader-Willi Syndrome 49
Jun 17, 2014: Essentialis Announces the Grant of its First Japanese Patent Which Provides Extensive Protection to DCCR in the Treatment of Prader-Willi Syndrome 50
May 28, 2014: Essentialis Obtains Orphan Drug Designation from FDA for DCCR in the Treatment of Prader-Willi Syndrome 50
Jan 15, 2014: Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2015 7
Number of Products under Development for Prader-Willi Syndrome (PWS) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Prader-Willi Syndrome (PWS) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 14
Prader-Willi Syndrome (PWS) - Pipeline by Essentialis, Inc., H1 2015 15
Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center S.A., H1 2015 16
Prader-Willi Syndrome (PWS) - Pipeline by LG Life Sciences, Ltd., H1 2015 17
Prader-Willi Syndrome (PWS) - Pipeline by P2D Bioscience, H1 2015 18
Prader-Willi Syndrome (PWS) - Pipeline by Pfizer Inc., H1 2015 19
Prader-Willi Syndrome (PWS) - Pipeline by Rhythm Pharmaceuticals, H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Prader-Willi Syndrome (PWS) Therapeutics - Recent Pipeline Updates, H1 2015 42